Cargando…

A high throughput bispecific antibody discovery pipeline

Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering...

Descripción completa

Detalles Bibliográficos
Autores principales: Segaliny, Aude I., Jayaraman, Jayapriya, Chen, Xiaoming, Chong, Jonathan, Luxon, Ryan, Fung, Audrey, Fu, Qiwei, Jiang, Xianzhi, Rivera, Rodrigo, Ma, Xiaoya, Ren, Ci, Zimak, Jan, Hedde, Per Niklas, Shang, Yonglei, Wu, George, Zhao, Weian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082157/
https://www.ncbi.nlm.nih.gov/pubmed/37029216
http://dx.doi.org/10.1038/s42003-023-04746-w
_version_ 1785021260227411968
author Segaliny, Aude I.
Jayaraman, Jayapriya
Chen, Xiaoming
Chong, Jonathan
Luxon, Ryan
Fung, Audrey
Fu, Qiwei
Jiang, Xianzhi
Rivera, Rodrigo
Ma, Xiaoya
Ren, Ci
Zimak, Jan
Hedde, Per Niklas
Shang, Yonglei
Wu, George
Zhao, Weian
author_facet Segaliny, Aude I.
Jayaraman, Jayapriya
Chen, Xiaoming
Chong, Jonathan
Luxon, Ryan
Fung, Audrey
Fu, Qiwei
Jiang, Xianzhi
Rivera, Rodrigo
Ma, Xiaoya
Ren, Ci
Zimak, Jan
Hedde, Per Niklas
Shang, Yonglei
Wu, George
Zhao, Weian
author_sort Segaliny, Aude I.
collection PubMed
description Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function.
format Online
Article
Text
id pubmed-10082157
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100821572023-04-09 A high throughput bispecific antibody discovery pipeline Segaliny, Aude I. Jayaraman, Jayapriya Chen, Xiaoming Chong, Jonathan Luxon, Ryan Fung, Audrey Fu, Qiwei Jiang, Xianzhi Rivera, Rodrigo Ma, Xiaoya Ren, Ci Zimak, Jan Hedde, Per Niklas Shang, Yonglei Wu, George Zhao, Weian Commun Biol Article Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function. Nature Publishing Group UK 2023-04-07 /pmc/articles/PMC10082157/ /pubmed/37029216 http://dx.doi.org/10.1038/s42003-023-04746-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Segaliny, Aude I.
Jayaraman, Jayapriya
Chen, Xiaoming
Chong, Jonathan
Luxon, Ryan
Fung, Audrey
Fu, Qiwei
Jiang, Xianzhi
Rivera, Rodrigo
Ma, Xiaoya
Ren, Ci
Zimak, Jan
Hedde, Per Niklas
Shang, Yonglei
Wu, George
Zhao, Weian
A high throughput bispecific antibody discovery pipeline
title A high throughput bispecific antibody discovery pipeline
title_full A high throughput bispecific antibody discovery pipeline
title_fullStr A high throughput bispecific antibody discovery pipeline
title_full_unstemmed A high throughput bispecific antibody discovery pipeline
title_short A high throughput bispecific antibody discovery pipeline
title_sort high throughput bispecific antibody discovery pipeline
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082157/
https://www.ncbi.nlm.nih.gov/pubmed/37029216
http://dx.doi.org/10.1038/s42003-023-04746-w
work_keys_str_mv AT segalinyaudei ahighthroughputbispecificantibodydiscoverypipeline
AT jayaramanjayapriya ahighthroughputbispecificantibodydiscoverypipeline
AT chenxiaoming ahighthroughputbispecificantibodydiscoverypipeline
AT chongjonathan ahighthroughputbispecificantibodydiscoverypipeline
AT luxonryan ahighthroughputbispecificantibodydiscoverypipeline
AT fungaudrey ahighthroughputbispecificantibodydiscoverypipeline
AT fuqiwei ahighthroughputbispecificantibodydiscoverypipeline
AT jiangxianzhi ahighthroughputbispecificantibodydiscoverypipeline
AT riverarodrigo ahighthroughputbispecificantibodydiscoverypipeline
AT maxiaoya ahighthroughputbispecificantibodydiscoverypipeline
AT renci ahighthroughputbispecificantibodydiscoverypipeline
AT zimakjan ahighthroughputbispecificantibodydiscoverypipeline
AT heddeperniklas ahighthroughputbispecificantibodydiscoverypipeline
AT shangyonglei ahighthroughputbispecificantibodydiscoverypipeline
AT wugeorge ahighthroughputbispecificantibodydiscoverypipeline
AT zhaoweian ahighthroughputbispecificantibodydiscoverypipeline
AT segalinyaudei highthroughputbispecificantibodydiscoverypipeline
AT jayaramanjayapriya highthroughputbispecificantibodydiscoverypipeline
AT chenxiaoming highthroughputbispecificantibodydiscoverypipeline
AT chongjonathan highthroughputbispecificantibodydiscoverypipeline
AT luxonryan highthroughputbispecificantibodydiscoverypipeline
AT fungaudrey highthroughputbispecificantibodydiscoverypipeline
AT fuqiwei highthroughputbispecificantibodydiscoverypipeline
AT jiangxianzhi highthroughputbispecificantibodydiscoverypipeline
AT riverarodrigo highthroughputbispecificantibodydiscoverypipeline
AT maxiaoya highthroughputbispecificantibodydiscoverypipeline
AT renci highthroughputbispecificantibodydiscoverypipeline
AT zimakjan highthroughputbispecificantibodydiscoverypipeline
AT heddeperniklas highthroughputbispecificantibodydiscoverypipeline
AT shangyonglei highthroughputbispecificantibodydiscoverypipeline
AT wugeorge highthroughputbispecificantibodydiscoverypipeline
AT zhaoweian highthroughputbispecificantibodydiscoverypipeline